High-dose infliximab therapy in Crohn's disease: Clinical experience, safety, and efficacy

Journal of Crohn's and Colitis

Volumn 9, Issue 3, 2015, Pages 266-275

  Hendler, Steven A ^a   Cohen, Benjamin L ^a   Colombel, Jean Frédéric ^a   Sands, Bruce E ^a   Mayer, Lloyd ^a   Agarwal, Shradha ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anti TNF; Biologic therapy; Crohn's disease; Dose intensification; Infliximab; Loss of response

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; GASTROINTESTINAL AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; CROHN DISEASE; DERMATITIS; DIARRHEA; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; GYNECOLOGIC INFECTION; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INFECTION; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYCOBACTERIOSIS; MYCOSIS; PERIANAL ABSCESS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SKIN CARCINOMA; SKIN INFECTION; SYSTEMIC MYCOSIS; TREATMENT DURATION; URINARY TRACT INFECTION; DRUG ADMINISTRATION; EVALUATION STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942566280     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jju026     Document Type: Article

References (25)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-9
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-35
3. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-85
4. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a costeffectiveness analysis. Aliment Pharmacol Ther 2007; 26:1509-20
5. Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007; 13:1093-9
6. Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose 'escalation' in patients losing response. J Clin Gastroenterol 2011; 45:113-8
7. Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012; 18:2026-33
8. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105:1133-9
9. Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001; 96:635-43
10. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogenous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012;382:177-88
11. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10:1079-87
12. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98:1315-24
13. Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011; 34:1-10
14. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-95
15. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:1248-54
16. Imaeda H, Bamba S, Takahashi K, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol 2014; 49:674-82
17. Casteele NV, Gils A, Ballet V, et al. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: Final results of the TAXIT study. United European Gastroenterology Journal 2013;1S:A1
18. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-405
19. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107:1409-22
20. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932-9
21. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014; 12:1474-81
22. Jurgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9:421-7
23. Magro F, Rodrigues-Pinto E, Santos-Antunes J, et al. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis 2014; 8:129-36
24. Bendtzen K. Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy 2012; 4:1167-79
25. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastreoenterol 2014; 109: 1250-6